文献速递生殖医学

一次IVF/ICSI失败后子宫内膜搔刮的随机对照试验(SCRaTCH)

Endometrial scratching in women with one failed IVF/ICSI cycle-outcomes of a randomised controlled trial (SCRaTCH).
PubMed 文献 · Hum Reprod · 2021-01-01

SCRaTCH试验为一项非盲随机对照试验,纳入933例一次IVF/ICSI治疗失败后拟行第二次新鲜IVF/ICSI的女性,评估单次子宫内膜活检导管搔刮能否提高后续治疗活产率。搔刮组新鲜移植后活产率较对照组高4.6%(110/465 vs 88/461,RR 1.24,95%CI 0.96-1.59),真实差异95%CI为-0.7%至+9.9%。随访12个月累积活产率搔刮组高5.1%(202/467 vs 178/466),真实差异95%CI为-1.2%至+11.4%。

要点

  • 单次子宫内膜搔刮后新鲜移植活产率提高4.6%,但95%CI跨零且下限达-0.7%。
  • 12个月累积活产率搔刮组高5.1%,真实差异95%CI为-1.2%至+11.4%。
  • 目前不建议在临床试验之外进行子宫内膜搔刮。

核心结论

  • 一次IVF/ICSI失败后单次子宫内膜搔刮可能提高后续新鲜IVF/ICSI活产率,但真实效应可能为零甚至轻微负值。
  • 目前证据不足以支持在临床试验外常规开展子宫内膜搔刮。

研究设计与样本

  • 非盲随机对照试验,在8家学术医院和24家综合医院开展。
  • 纳入933例一次IVF/ICSI治疗失败且计划第二次新鲜IVF/ICSI的女性(1065例合格中纳入933例,参与率88%)。
  • 干预为单次子宫内膜活检导管搔刮,对照为不搔刮,比较后续IVF/ICSI新鲜移植后活产率。

主要发现

  • 新鲜移植后搔刮组活产110/465,对照组88/461,搔刮组高4.6%,RR 1.24(95%CI 0.96-1.59)。
  • 真实差异95%CI为-0.7%至+9.9%,最大比例区间为正但可能无效应或轻微负效应。
  • 生化妊娠丢失搔刮组27/153、对照组19/130,RR 1.21(95%CI 0.71-2.07);流产搔刮组14/126、对照组17/111,RR 0.73(95%CI 0.38-1.40)。
  • 12个月随访累积活产搔刮组202/467、对照组178/466,搔刮组高5.1%,真实差异95%CI为-1.2%至+11.4%。

关键数值与推荐

  • 主要结局为后续新鲜IVF/ICSI移植后活产率。
  • 次要结局包括12个月累积持续妊娠致活产率、生化妊娠丢失和流产率。
  • 研究效能设定为检测9%的活产率差异。

临床怎么用

  • 不应在临床试验之外对一次IVF/ICSI失败女性常规行子宫内膜搔刮。
  • 与患者沟通时应说明搔刮的潜在获益不确定,真实效应可能为零或轻微负值。

局限性

  • 研究为非盲设计,分配分组可知情可能影响患者继续治疗的决策。
  • 研究效能仅能检测9%的活产率差异,不足以排除更小效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does endometrial scratching in women with one failed IVF/ICSI treatment affect the chance of a live birth of the subsequent fresh IVF/ICSI cycle? SUMMARY ANSWER: In this study, 4.6% more live births were observed in the scratch group, with a likely certainty range between -0.7% and +9.9%. WHAT IS KNOWN ALREADY: Since the first suggestion that endometrial scratching might improve embryo implantation during IVF/ICSI, many clinical trials have been conducted. However, due to limitations in sample size and study quality, it remains unclear whether endometrial scratching improves IVF/ICSI outcomes. STUDY DESIGN, SIZE, DURATION: The SCRaTCH trial was a non-blinded randomised controlled trial in women with one unsuccessful IVF/ICSI cycle and assessed whether a single endometrial scratch using an endometrial biopsy catheter would lead to a higher live birth rate after the subsequent IVF/ICSI treatment compared to no scratch. The study took place in 8 academic and 24 general hospitals. Participants were randomised between January 2016 and July 2018 by a web-based randomisation programme. Secondary outcomes included cumulative 12-month ongoing pregnancy leading to live birth rate. PARTICIPANTS/MATERIALS, SETTING, METHODS: Women with one previous failed IVF/ICSI treatment and planning a second fresh IVF/ICSI treatment were eligible. In total, 933 participants out of 1065 eligibles were included (participation rate 88%). MAIN RESULTS AND THE ROLE OF CHANCE: After the fresh transfer, 4.6% more live births were observed in the scratch compared to control group (110/465 versus 88/461, respectively, risk ratio (RR) 1.24 [95% CI 0.96-1.59]). These data are consistent with a true difference of between -0.7% and +9.9% (95% CI), indicating that while the largest proportion of the 95% CI is positive, scratching could have no or even a small negative effect. Biochemical pregnancy loss and miscarriage rate did not differ between the two groups: in the scratch group 27/153 biochemical pregnancy losses and 14/126 miscarriages occurred, while this was 19/130 and 17/111 for the control group (RR 1.21 (95% CI 0.71-2.07) and RR 0.73 (95% CI 0.38-1.40), respectively). After 12 months of follow-up, 5.1% more live births were observed in the scratch group (202/467 versus 178/466), of which the true difference most likely lies between -1.2% and +11.4% (95% CI). LIMITATIONS, REASONS FOR CAUTION: This study was not blinded. Knowledge of allocation may have been an incentive for participants allocated to the scratch group to continue treatment in situations where they may otherwise have cancelled or stopped. In addition, this study was powered to detect a difference in live birth rate of 9%. WIDER IMPLICATIONS OF THE FINDINGS: The results of this study are an incentive for further assessment of the efficacy and clinical implications of endometrial scratching. If a true effect exists, it may be smaller than previously anticipated or may be limited to specific groups of women undergoing IVF/ICSI. Studying this will require larger sample sizes, which will be provided by the ongoing international individual participant data-analysis (PROSPERO CRD42017079120). At present, endometrial scratching should not be performed outside of clinical trials. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by ZonMW, the Dutch organisation for funding healthcare research. J.S.E. Laven reports grants and personal fees from AnshLabs (Webster, Tx, USA), Ferring (Hoofddorp, The Netherlands) and Ministry of Health (CIBG, The Hague, The Netherlands) outside the submitted work. A.E.P. Cantineau reports 'other' from Ferring BV, personal fees from Up to date Hyperthecosis, 'other' from Theramex BV, outside the submitted work. E.R. Groenewoud reports grants from Titus Health Care during the conduct of the study. A.M. van Heusden reports personal fees from Merck Serono, personal fees from Ferring, personal fees from Goodlife, outside the submitted work. F.J.M. Broekmans reports personal fees as Member of the external advisory board for Ferring BV, The Netherlands, personal fees as Member of the external advisory board for Merck Serono, The Netherlands, personal fees as Member of the external advisory for Gedeon Richter, Belgium, personal fees from Educational activities for Ferring BV, The Netherlands, grants from Research support grant Merck Serono, grants from Research support grant Ferring, personal fees from Advisory and consultancy work Roche, outside the submitted work. C.B. Lambalk reports grants from Ferring, grants from Merck, grants from Guerbet, outside the submitted work. TRIAL REGISTRATION NUMBER: Registered in the Netherlands Trial Register (NL5193/NTR 5342). TRIAL REGISTRATION DATE: 31 July 2015. DATE OF FIRST PATIENT’S ENROLMENT: 26 January 2016.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. van Hoogenhuijze NE, Mol F, Laven JSE, et al. Endometrial scratching in women with one failed IVF/ICSI cycle-outcomes of a randomised controlled trial (SCRaTCH). Hum Reprod. 2021. PMID: 33289528. doi:10.1093/humrep/deaa268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。